Nevakar Injectables Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
53
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.6M
- Investors
-
4
Nevakar Injectables General Information
Description
Developer of ready-to-use injectable medications intended for critical care and hospital settings. The company's technology streamlines medication preparation by providing pre-filled syringes and vials that eliminate the need for manual mixing by hospital staff, enabling healthcare professionals to improve medication accuracy, reduce the risk of errors, and save time during critical situations.
Contact Information
Website
www.nevakarinjectables.comCorporate Office
- 1019 U.S. Highway 202-206
- Building K, New Jersey Center of Excellence
- Bridgewater, NJ 08807
- United States
Corporate Office
- 1019 U.S. Highway 202-206
- Building K, New Jersey Center of Excellence
- Bridgewater, NJ 08807
- United States
Nevakar Injectables Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 08-Aug-2023 | $4.6M | Completed | Clinical Trials - Phase 2 | ||
| 6. Later Stage VC | 23-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | Completed | Clinical Trials - Phase 2 | ||||
| 4. Debt - PPP | 09-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Debt - General | 18-Jun-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Debt - General | 29-Nov-2018 | $20M | $75M | Completed | Clinical Trials - Phase 2 | |
| 1. Angel (individual) | 27-Jul-2016 | $55M | $55M | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nevakar Injectables Comparisons
Industry
Financing
Details
Nevakar Injectables Competitors (4)
One of Nevakar Injectables’s 4 competitors is Mati Therapeutics, a Venture Capital-Backed company based in Austin, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mati Therapeutics | Venture Capital-Backed | Austin, TX | ||||
| TearClear | Venture Capital-Backed | Princeton, NJ | ||||
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | ||||
| EyeD Pharma | Venture Capital-Backed | Seraing, Belgium |
Nevakar Injectables Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nevakar Injectables Patents
Nevakar Injectables Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260232647-A1 | Stable compositions of bupivacaine hydrochloride | Pending | 07-Feb-2025 | ||
| WO-2025015011-A1 | Bupivacaine compositions and methods | Inactive | 10-Jul-2023 | ||
| WO-2024182731-A1 | Injectable compositions of vitamers of vitamin b12 and uses thereof | Inactive | 01-Mar-2023 | ||
| WO-2022256545-A1 | Injectable pregabalin formulations | Inactive | 04-Jun-2021 | ||
| WO-2022183055-A1 | Sodium bicarbonate injectable formulation and methods of use thereof | Inactive | 26-Feb-2021 | A61K33/10 |
Nevakar Injectables Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nevakar Injectables Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| H.I.G. HealthBridge Partners | Growth/Expansion | Minority | ||
| Hybridge Capital Management | Real Estate | Minority | ||
| Oxford Finance | Lender/Debt Provider | Minority | ||
| Werth Ventures | Family Office | Minority |
Nevakar Injectables FAQs
-
When was Nevakar Injectables founded?
Nevakar Injectables was founded in 2015.
-
Where is Nevakar Injectables headquartered?
Nevakar Injectables is headquartered in Bridgewater, NJ.
-
What is the size of Nevakar Injectables?
Nevakar Injectables has 53 total employees.
-
What industry is Nevakar Injectables in?
Nevakar Injectables’s primary industry is Drug Delivery.
-
Is Nevakar Injectables a private or public company?
Nevakar Injectables is a Private company.
-
What is Nevakar Injectables’s current revenue?
The current revenue for Nevakar Injectables is .
-
How much funding has Nevakar Injectables raised over time?
Nevakar Injectables has raised $248M.
-
Who are Nevakar Injectables’s investors?
H.I.G. HealthBridge Partners, Hybridge Capital Management, Oxford Finance, and Werth Ventures have invested in Nevakar Injectables.
-
Who are Nevakar Injectables’s competitors?
Mati Therapeutics, TearClear, Adverum Biotechnologies, and EyeD Pharma are competitors of Nevakar Injectables.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
